1. The drug – ATL1103
2.
3.
4. Development path and strategy going forward
Post this trial and with successful outcomes, Antisense Therapeutics would then look to partner ATL1103 for the sight disorders/cancers indications with drug development and commercialisation companies in those specialized fields. Antisense would look to continue its own development of ATL1103 for growth disorders (acromegaly) to further enhance the value of the drug for this indication by conducting additional clinical trials (Phase II initially). As the disease acromegaly is designated orphan drug status, development of ATL1103 is more affordable and the registration process more stream-lined, making acromegaly an ideal lead indication for Antisense to further develop.
http://www.finnewsnetwork.com.au
1. The drug – ATL11032.3.4. Development path and strategy going...
-
- There are more pages in this discussion • 52 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
